opdivo solution
bristol-myers squibb canada - nivolumab - solution - 10mg - nivolumab 10mg - antineoplastic agents
opdivo solution
bristol-myers squibb canada - nivolumab - solution - 10mg - nivolumab 10mg - antineoplastic agents
memantine hydrochloride 10 mg/ml oral solution
rosemont pharmaceuticals ltd - memantine hydrochloride - oral solution - 10 mg/ml - other anti-dementia drugs
memantinast oral solution
one pharma industrial pharmaceutical company societe anonyme - memantine (memantine hydrochloride) - oral solution - 5mg/0.5ml
opdivo 40mg4ml concentrate for solution for infusion vials
bristol-myers squibb pharmaceuticals ltd - nivolumab - solution for infusion - 10mg/1ml
opdivo 100mg10ml concentrate for solution for infusion vials
bristol-myers squibb pharmaceuticals ltd - nivolumab - solution for infusion - 10mg/1ml
cabometyx cabozantinib (as (s)-malate) 60 mg film-coated tablet bottle
ipsen pty ltd - cabozantinib (s)-malate, quantity: 76.03 mg (equivalent: cabozantinib, qty 60 mg) - tablet, film coated - excipient ingredients: titanium dioxide; magnesium stearate; hypromellose; triacetin; colloidal anhydrous silica; iron oxide yellow; hyprolose; lactose; croscarmellose sodium; microcrystalline cellulose - renal cell carcinoma (rcc),cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):,- in treatment-na?ve adults with intermediate or poor risk,- in adults following prior treatment with vascular endothelial growth factor targeted therapy.,cabometyx in combination with nivolumab is indicated for the first-line treatment of advanced renal cell carcinoma.,hepatocellular carcinoma (hcc),cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.,differentiated thyroid carcinoma (dtc),cabometyx is indicated as monotherapy for the treatment of adult and paediatric patients aged 12 years and older with locally advanced or metastatic differentiated thyroid carcinoma (dtc) that has progressed during or after prior vegfr-targeted therapy and who are radioactive iodine (rai) refractory or ineligible.
opdualag
bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.
imovax rabies powder for suspension
sanofi pasteur limited - rabies vaccine inactivated (human diploid-cell culture) - powder for suspension - 2.5unit - rabies vaccine inactivated (human diploid-cell culture) 2.5unit - vaccines
opdivo 10mgml concentrate for solution for infusion
dksh malaysia sdn. bhd. - nivolumab -